Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Baback Roshanravan, MD/MPH (ucdavis)

Description

Summary

Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify novel mechanisms to improve the efficiency of exercise. This will also serve to prevent frailty, sarcopenia, and muscle dysfunction in patients with ESRD.

Official Title

Role of Mitochondrial Dysfunction in the Response to Exercise in Patients with Advance Kidney Disease

Details

Keywords

End Stage Renal Disease, mitochondrial dysfunction, CoQ10, sarcopenia, frailty, High-intensity interval training (HIIT), exercise, magnetic resonance spectroscopy (P-MRS), physical performance tests, Kidney Diseases, Chronic Kidney Failure, Mitochondrial Diseases, Ubiquinone, HB-HIIT, HB HIIT + CoQ10

Eligibility

Locations

  • University of California Davis Health not yet accepting patients
    Sacramento California 95817 United States
  • Vanderbilt University Medical Center-GCRC accepting new patients
    Nashville Tennessee 37232 United States

Lead Scientist at University of California Health

  • Baback Roshanravan, MD/MPH (ucdavis)
    Professor, MED: Int Med Nephrology, School of Medicine. Authored (or co-authored) 45 research publications

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Vanderbilt University Medical Center
ID
NCT05422534
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 156 study participants
Last Updated